Post-Anesthesia Care and Recovery Management Flashcards

A patient in the post-anesthesia recovery phase develops laryngospasm following extubation. After repositioning the airway and applying positive pressure ventilation without improvement, which pharmacologic intervention is most appropriate?

Answer: Succinylcholine 0.1–0.2 mg/kg IV to break the spasm

When laryngospasm does not resolve with jaw thrust, airway repositioning, and positive-pressure oxygen, a sub-paralytic ('lytic') dose of succinylcholine (0.1–0.2 mg/kg IV) is the definitive pharmacologic treatment to relax the spasming vocal cords. Full paralytic doses (1–1.5 mg/kg) are reserved for complete obstruction. Atropine, flumazenil, and naloxone do not address the muscular mechanism of laryngospasm.

During phase I recovery after IV sedation, a 58-year-old male patient's ETCO₂ waveform shows a prolonged sloping upstroke with an elevated plateau of 52 mmHg. He is breathing spontaneously but his SpO₂ is 94% on 4 L/min nasal cannula. Which condition best explains this capnography pattern?

Answer: Bronchospasm or chronic obstructive pulmonary disease causing air trapping

A sloped, 'shark-fin' upstroke on capnography combined with an elevated EtCO₂ plateau is the hallmark of obstructive physiology — bronchospasm, COPD, or asthma — where uneven emptying of alveoli with different time constants creates a prolonged expiratory phase. Central respiratory depression from opioids lowers rate but preserves the waveform shape and typically shows a normal plateau. Laryngospasm usually produces no waveform (complete obstruction) or a severely distorted one. Pulmonary embolism causes a low EtCO₂ (increased dead space), not a high one.

A 34-year-old patient emerging from propofol/fentanyl sedation suddenly develops muscle rigidity, hyperthermia (39.8°C), diaphoresis, and agitation in the recovery area. Heart rate is 138 bpm. She was also taking sertraline. Which diagnosis should be considered first and what is the immediate priority?

Answer: Serotonin syndrome; discontinue all serotonergic agents and provide supportive cooling and benzodiazepines

The clinical triad of altered mental status, autonomic instability, and neuromuscular abnormalities (rigidity/clonus) in a patient on a serotonergic drug (sertraline) plus fentanyl (a weak serotonin reuptake inhibitor) points to serotonin syndrome. Malignant hyperthermia requires a triggering volatile agent or succinylcholine and presents with rising CO₂ and severe metabolic acidosis — propofol is not a trigger. NMS develops over days, not minutes. Management of serotonin syndrome includes stopping serotonergic agents, benzodiazepines for agitation/rigidity, active cooling, and cyproheptadine in moderate-severe cases.

In post-anesthesia care, Aldrete scoring is used to determine readiness for discharge. A patient scores 2 on activity, 2 on respiration, 1 on circulation (BP ±30 mmHg from baseline), 2 on consciousness, and 1 on oxygen saturation (SpO₂ 90–91% on supplemental oxygen). What is the correct interpretation?

Answer: The patient is NOT ready for discharge; the modified Aldrete score of 8 does not meet the threshold of ≥9

The modified Aldrete (post-anesthetic recovery) score ranges from 0–10. A minimum score of ≥9 is required before discharge from phase I recovery. This patient scores 8 (2+2+1+2+1), which falls below the threshold. The score counts SpO₂ even on supplemental oxygen — a value of 90–91% on O₂ scores 1 rather than 2. Individual scores of 1 are not absolute contraindications but do reduce the total, and the total must meet the threshold. Only a score of 0 in the SpO₂ category would itself require immediate intervention regardless of total score.

A patient who received midazolam and fentanyl for an oral surgery procedure is being monitored in recovery. Forty-five minutes post-procedure, the nurse notices the patient has a respiratory rate of 6 breaths/min and SpO₂ of 87% despite supplemental oxygen. Naloxone 0.4 mg IV is administered but there is only minimal improvement in respiratory rate and SpO₂ remains at 89%. What is the most likely explanation and next step?

Answer: Residual benzodiazepine contribution; administer flumazenil 0.2 mg IV titrated to effect

When naloxone partially reverses respiratory depression but improvement is incomplete, residual benzodiazepine effect (from midazolam) is the most likely co-contributor. Midazolam and fentanyl have synergistic respiratory depressant effects. After reversing opioid contribution with naloxone, the remaining depression may be benzodiazepine-mediated and responds to flumazenil 0.2 mg IV (titrated in 0.1 mg increments, max 1 mg). Immediate re-dosing of naloxone without addressing the benzodiazepine component is unlikely to achieve adequate reversal. Airway obstruction would not respond to pharmacologic reversal agents and would present with paradoxical breathing.

An adult patient in post-anesthesia recovery has received reversal agents and is now alert, breathing at 14 breaths/min with SpO₂ 97% on room air, and Aldrete score of 9. However, the patient reports pain rated 8/10. The anesthesia provider plans to discharge the patient to phase II recovery. Which statement best reflects current evidence-based post-anesthesia care standards?

Answer: Discharge to phase II is premature; pain must be controlled to a tolerable level (typically ≤4/10) before phase transfer

While the original Aldrete score does not explicitly include pain, current evidence-based standards and most institutional protocols require adequate pain control (generally ≤4/10 or patient-acceptable level) as a criterion before phase transfer. Undertreated severe pain (8/10) also carries the risk of hemodynamic instability, patient movement, and nausea. Discharging on Aldrete score alone without addressing pain is not considered best practice. The correct approach is to treat pain to an acceptable level before phase transfer, not simply observe for an arbitrary 30 minutes before deciding.